These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 35212134)
21. Utility of CD229 as novel marker in measurable residual disease assessment in multiple myeloma-An evidence-based approach. Rai S; Das N; Gupta R; Kumar L; Sharma A; Singh S; Prajapati VK Int J Lab Hematol; 2023 Apr; 45(2):179-186. PubMed ID: 36403963 [TBL] [Abstract][Full Text] [Related]
22. Inability of a monoclonal anti-light chain antibody to detect clonal plasma cells in a patient with multiple myeloma by multicolor flow cytometry. van Velzen JF; van den Blink D; Bloem AC Cytometry B Clin Cytom; 2013; 84(1):30-2. PubMed ID: 23019187 [TBL] [Abstract][Full Text] [Related]
23. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. Ocqueteau M; Orfao A; Almeida J; Bladé J; González M; García-Sanz R; López-Berges C; Moro MJ; Hernández J; Escribano L; Caballero D; Rozman M; San Miguel JF Am J Pathol; 1998 Jun; 152(6):1655-65. PubMed ID: 9626070 [TBL] [Abstract][Full Text] [Related]
24. Immunophenotypic heterogeneity of normal plasma cells: comparison with minimal residual plasma cell myeloma. Liu D; Lin P; Hu Y; Zhou Y; Tang G; Powers L; Medeiros LJ; Jorgensen JL; Wang SA J Clin Pathol; 2012 Sep; 65(9):823-9. PubMed ID: 22685235 [TBL] [Abstract][Full Text] [Related]
26. [Analysis of cell morphology and immunophenotypic characteristics in 47 cases of multiple myeloma]. Su XD; Lin R; Xu XL; Chen X; Zhan WL; Zheng JP; Fan CL Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Feb; 23(1):137-41. PubMed ID: 25687061 [TBL] [Abstract][Full Text] [Related]
27. CD19-CD45 low/- CD38 high/CD138+ plasma cells enrich for human tumorigenic myeloma cells. Kim D; Park CY; Medeiros BC; Weissman IL Leukemia; 2012 Dec; 26(12):2530-7. PubMed ID: 22733078 [TBL] [Abstract][Full Text] [Related]
28. Impact of CD138 Magnetic Bead-based Positive Selection on Bone Marrow Plasma Cell Surface Markers. Bansal R; Kimlinger T; Gyotoku KA; Smith M; Rajkumar V; Kumar S Clin Lymphoma Myeloma Leuk; 2021 Jan; 21(1):e48-e51. PubMed ID: 32873534 [TBL] [Abstract][Full Text] [Related]
29. [Comparison of minimal residual disease in multiple myeloma patients detected by 8-color panels and next generation flow cytometry]. Wang XF; Wang TT; Zhang ZY; Zhou HX; Zhang YR; Chen WM; Geng CY Zhonghua Xue Ye Xue Za Zhi; 2019 Jun; 40(6):512-517. PubMed ID: 31340626 [No Abstract] [Full Text] [Related]
30. The immunophenotypic stability of plasma cell myeloma by flow cytometry. Spears MD; Olteanu H; Kroft SH; Harrington AM Int J Lab Hematol; 2011 Oct; 33(5):483-91. PubMed ID: 21470371 [TBL] [Abstract][Full Text] [Related]
31. [Immunophenotype characteristics of patients with multiple myeloma in different risk stratification]. Hu K; Wang J; Zhu MX; Wang YF; Ke XY Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Dec; 22(6):1624-7. PubMed ID: 25543486 [TBL] [Abstract][Full Text] [Related]
32. An approach for diagnosing plasma cell myeloma by three-color flow cytometry based on kappa/lambda ratios of CD38-gated CD138(+) cells. Nakayama S; Yokote T; Hirata Y; Iwaki K; Akioka T; Miyoshi T; Takayama A; Nishiwaki U; Masuda Y; Ikemoto T; Tanaka H; Nishimura Y; Tsuji M; Hanafusa T Diagn Pathol; 2012 Sep; 7():131. PubMed ID: 23021410 [TBL] [Abstract][Full Text] [Related]
33. Flow Cytometric Evaluation of Traditional and Novel Surface Markers for the Diagnosis of Plasma Cell Dyscrasias. Draxler DF; Wutzlhofer LM; Slavka G; Hübl W; Ludwig H; Schreder M; Reynolds J; Willheim M Indian J Hematol Blood Transfus; 2019 Oct; 35(4):673-682. PubMed ID: 31741619 [TBL] [Abstract][Full Text] [Related]
34. Increased circulating plasma cells detected by flow cytometry predicts poor prognosis in patients with plasma cell myeloma. Bae MH; Park CJ; Kim BH; Cho YU; Jang S; Lee DH; Seo EJ; Yoon DH; Lee JH; Suh C Cytometry B Clin Cytom; 2018 May; 94(3):493-499. PubMed ID: 29220877 [TBL] [Abstract][Full Text] [Related]
35. Phenotype of plasma cells in multiple myeloma and monoclonal gammopathy of undetermined significance. Kovarova L; Buresova I; Buchler T; Suska R; Pour L; Zahradova L; Penka M; Hajek R Neoplasma; 2009; 56(6):526-32. PubMed ID: 19728762 [TBL] [Abstract][Full Text] [Related]
36. Immunophenotypic Characterization and Ploidy Analysis of Neoplastic Plasma Cells by Multiparametric Flow Cytometry. Gupta R; Gupta P; Rahman K; Biswas S; Chandra D; Singh MK; Sarkar MK; Gupta A; Nityanand S Indian J Hematol Blood Transfus; 2022 Jul; 38(3):473-480. PubMed ID: 35747566 [TBL] [Abstract][Full Text] [Related]
37. Multiple myeloma expressing CD19(+)CD56(-) phenotype. Sahara N; Ihara M; Ono T; Tamashima S; Matsui H; Takeshita A; Ohno R Am J Hematol; 2000 Aug; 64(4):311-3. PubMed ID: 10911386 [TBL] [Abstract][Full Text] [Related]
38. [Recent advances on the prognostic value of immunophenotyping in multiple myeloma by flow cytometry]. Guo J; Chang CK; Su JY; Zhang X; Li X Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):1178-82. PubMed ID: 25130852 [TBL] [Abstract][Full Text] [Related]
39. Immunophenotypic features by multiparameter flow cytometry can help distinguish low grade B-cell lymphomas with plasmacytic differentiation from plasma cell proliferative disorders with an unrelated clonal B-cell process. Rosado FG; Morice WG; He R; Howard MT; Timm M; McPhail ED Br J Haematol; 2015 May; 169(3):368-76. PubMed ID: 25644063 [TBL] [Abstract][Full Text] [Related]
40. Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders. Raja KR; Kovarova L; Hajek R Br J Haematol; 2010 May; 149(3):334-51. PubMed ID: 20201947 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]